AVEO Pharmaceuticals - AVEO Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVEO shares.
View AVEO analyst ratings or view top-rated stocks.

2 brokers have issued 1 year target prices for AVEO Pharmaceuticals' stock. Their AVEO share price forecasts range from $18.00 to $18.00. On average, they predict the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 130.8% from the stock's current price.
View analysts price targets for AVEO or view top-rated stocks among Wall Street analysts.

AVEO Pharmaceuticals' stock was trading at $4.69 at the beginning of the year. Since then, AVEO stock has increased by 66.3% and is now trading at $7.80.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AVEO earnings forecast.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its quarterly earnings data on Thursday, August, 4th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. AVEO Pharmaceuticals had a negative trailing twelve-month return on equity of 87.81% and a negative net margin of 45.72%. During the same quarter in the previous year, the firm earned ($0.48) earnings per share.

AVEO Pharmaceuticals's stock reverse split on Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

AVEO Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.36%), Brandywine Global Investment Management LLC (0.32%), Northern Trust Corp (0.15%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Michael Ferraresso, Michael P Bailey and Peter W Sonsini.
View institutional ownership trends.

Shares of AVEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVEO stock can currently be purchased for approximately $7.80.

AVEO Pharmaceuticals (NASDAQ:AVEO) has a market capitalization of $269.96 million and generates $42.29 million in revenue each year. The biopharmaceutical company earns $-53,340,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

The company employs 114 workers across the globe.

AVEO Pharmaceuticals was founded in 2001.

AVEO Pharmaceuticals' mailing address is 30 WINTER STREET, BOSTON MA, 02108. The official website for the company is www.aveooncology.com. The biopharmaceutical company can be reached via phone at (617) 400-0101, via email at ir@aveooncology.com, or via fax at 617-995-4995.